RLMD
Relmada Therapeutics, Inc. · Healthcare
Director Paul Edward Kelly sold $64K of Relmada Therapeutics, Inc.
Sold$63,774
$35.43Price
1,800Shares
−1%Stake
What RLMD did after the filing
- The stock from Wed, Jan 27 open, $34.00
- +5.7%
- S&P 500, same days
- +3.5%
Measured over 30 trading days, to the Mar 11 close.
Traded Fri, Jan 22. Filed Wed, Jan 27, 1:48 AM ET, before the open. Returns use the Jan 27 open and the Mar 11 close. Not investment advice.